Optimizing Obesity Management With GLP-1 Agonist Medication Through Mobile Health Technology, Nutrition Therapy, and...

Area of Science:

• Metabolic Health and Endocrinology
• Obesity and Weight Management
• Cardiovascular Risk Reduction

Background:

• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for obesity treatment but often cause substantial skeletal muscle mass loss.
• Limited real-world data exists on lifestyle interventions to preserve muscle mass and mitigate cardiometabolic risks during GLP-1 RA therapy.

Purpose of the Study:

• To evaluate the TouchCare Method, a lifestyle intervention, in conjunction with GLP-1 RAs.
• To assess the impact of the TouchCare Method on body composition and cardiometabolic risk factors.

Main Methods:

• Retrospective chart review of 187 patients using the TouchCare Method (nutrition, exercise, self-monitoring) with GLP-1 RAs for at least 12 months.
• Primary outcomes: ≥10% weight loss, skeletal muscle mass proportion of weight loss, and changes in lipids, HbA1c, and blood pressure.

Main Results:

• 69.56% of patients achieved clinically significant weight loss (≥10%); skeletal muscle loss was 12.22% ± 8.73% of total weight loss.
• Significant improvements observed in glycemic control (74.7% of prediabetics reached euglycemia), blood pressure, and lipid profiles (Total-C, LDL-C, ApoB) (p < 0.001).

Conclusions:

• The TouchCare Method, a structured lifestyle intervention, may enhance GLP-1 RA efficacy.
• This approach supports significant weight loss, preserves skeletal muscle mass, and improves cardiometabolic risk factors.